AU2002231122A1 - Methods of treating anxiety disorders - Google Patents

Methods of treating anxiety disorders

Info

Publication number
AU2002231122A1
AU2002231122A1 AU2002231122A AU3112202A AU2002231122A1 AU 2002231122 A1 AU2002231122 A1 AU 2002231122A1 AU 2002231122 A AU2002231122 A AU 2002231122A AU 3112202 A AU3112202 A AU 3112202A AU 2002231122 A1 AU2002231122 A1 AU 2002231122A1
Authority
AU
Australia
Prior art keywords
alkyl
radical
methods
anxiety disorders
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231122A
Inventor
Mark Robert Bowlby
Sharon Joy Rosenzweig-Lipson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2002231122A1 publication Critical patent/AU2002231122A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention provides methods for treating, preventing or inhibiting anxiety, anxiety-related conditions and phobias in a mammal using compounds of the formula: wherein: R1 is H, alkyl, alkanoyl or the radical Ar; R2 is H or alkyl; R3 is alkoxy, NH2, alkylamino, dialkylamino, amino substituted by the radical Ar, alkyl, alkenyl, alkynyl, or the radicals Ar or ArO-; R4 is H, alkyl or the radical Ar; R5 is H or alkyl or the radical Ar; or a pharmaceutically acceptable salt or ester form thereof; Ar is an optionally substituted phenyl radical; and n is 0 or 1, or a pharmaceutically acceptable salt or ester form thereof, with the methods particularly including the use of N-[2-amino-4-(4-fluorobenzylamino)-phenyl]carbamic acid ethyl ester, also known as retigabine.
AU2002231122A 2000-12-20 2001-12-19 Methods of treating anxiety disorders Abandoned AU2002231122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25683400P 2000-12-20 2000-12-20
US60/256,834 2000-12-20
PCT/US2001/049362 WO2002049628A2 (en) 2000-12-20 2001-12-19 Methods of treating anxiety disorders

Publications (1)

Publication Number Publication Date
AU2002231122A1 true AU2002231122A1 (en) 2002-07-01

Family

ID=22973775

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231122A Abandoned AU2002231122A1 (en) 2000-12-20 2001-12-19 Methods of treating anxiety disorders

Country Status (9)

Country Link
US (1) US6589986B2 (en)
EP (1) EP1343495B1 (en)
JP (1) JP2004518653A (en)
AT (1) ATE421321T1 (en)
AU (1) AU2002231122A1 (en)
CA (1) CA2431278A1 (en)
DE (1) DE60137540D1 (en)
MX (1) MXPA03005497A (en)
WO (1) WO2002049628A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183395A1 (en) * 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US7632866B2 (en) * 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CN100448867C (en) * 2002-12-27 2009-01-07 H·隆德贝克有限公司 1,2,4-triaminobenzenderivater nyttige for behandling AV forstyrrelser i sentralnervesystemet
DE60312736T2 (en) 2002-12-27 2007-12-06 H. Lundbeck A/S, Valby 1,2,4-Triaminobenzene derivatives for the treatment of diseases of the central nervous system
MXPA05010000A (en) 2003-03-21 2005-11-17 Lundbeck & Co As H Substituted p-diaminobenzene derivatives.
US20060264496A1 (en) * 2003-04-25 2006-11-23 H. Lundbeck A/S Substituted indoline and indole derivatives
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7812020B2 (en) 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
DK2061465T3 (en) * 2006-08-23 2013-07-08 Valeant Pharmaceuticals Int Derivatives of 4- (N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2009037707A2 (en) 2007-09-20 2009-03-26 Ramot At Tel Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
CA2731008A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
EP2844639A4 (en) * 2012-04-30 2015-12-23 Scifluor Life Sciences Llc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US11358930B2 (en) 2018-04-20 2022-06-14 University of Pittsburgh—of the Commonwealth System of Higher Education Selective potassium channel agonists
WO2021113802A1 (en) * 2019-12-06 2021-06-10 Icahn School Of Medicine At Mount Sinai Method of treatment with kcnq channel openers
WO2021211867A1 (en) * 2020-04-16 2021-10-21 Attune Neurosciences, Inc. Kv7 modulators for treating sleep or anxiety disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (en) * 1992-01-08 1993-07-15 Asta Medica Ag NEW 1,2,4-TRIAMINOBENZOL DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DE19539861A1 (en) 1995-10-26 1997-04-30 Asta Medica Ag Use of 4-amino-4- (4-fluorobenzylamino) -1-ethoxy-carbonylaminobenzen for the prophylaxis and treatment of the consequences of acute and chronic cerebral low blood circulation and neurodegenerative diseases
DE19701694A1 (en) 1997-01-20 1998-07-23 Asta Medica Ag New modifications of the 2-amino-4- (4-fluorobenzylamino) -l-ethoxycarbonyl-aminobenzen and processes for their preparation
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
BR0012934A (en) 1999-08-04 2003-07-29 Icagen Inc Processes for reducing pain and anxiety
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
WO2001010380A2 (en) 1999-08-04 2001-02-15 Icagen, Inc. Benzanilides as potassium channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain

Also Published As

Publication number Publication date
EP1343495A2 (en) 2003-09-17
US6589986B2 (en) 2003-07-08
DE60137540D1 (en) 2009-03-12
WO2002049628A2 (en) 2002-06-27
CA2431278A1 (en) 2002-06-27
MXPA03005497A (en) 2003-10-06
US20020111379A1 (en) 2002-08-15
JP2004518653A (en) 2004-06-24
WO2002049628A3 (en) 2002-10-17
ATE421321T1 (en) 2009-02-15
EP1343495B1 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
AU2002231122A1 (en) Methods of treating anxiety disorders
DK0775129T3 (en) 3-Benzoylbenzofuran derivatives as thyroid hormone antagonists
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
GR3034398T3 (en) 2-[1&#39;,2&#39;,4&#39;-triazol-3&#39;-yloxymethylene]-anilides and their use as pest-control agents
YU57603A (en) Phosphodiesterase 4 inhibitors
DK0667866T3 (en) 1,4-benzothiazepines useful as neurological agents
JO2321B1 (en) 4-phenyl-pyridine derivatives
NZ507560A (en) Hydroxamic acid derivatives as antibacterials
YU67703A (en) Carbamate compounds for use in preventing or treating movement disorders
EP2289887A3 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
KR950701904A (en) Substituted (arylalkoxybenzyl) aminopropanamide derivatives, their preparation and use as anti-epileptic neuroprotective and antidepressant agents
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
ATE101040T1 (en) DERIVATIVES AND ANALOGUES OF PYRIMIDONE FOR THE TREATMENT OF ASTHMA AND CERTAIN SKIN DISEASES.
BR9606429A (en) Compound composition and process for treatment of dysfunction mediated by uPar- or uPa-
DE69911373D1 (en) AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES
BR9809685B1 (en) fungicidal mixture, process for controlling harmful fungi, use of a compound, and composition.
DE69916577D1 (en) AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
BG105126A (en) Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity
WO2002088091A3 (en) Inhibitors of human rhinovirus 2a cysteine protease
HUP0303400A2 (en) Herbicidal benzoyl cyclohexane diones, intermediates and use thereof
ATE270295T1 (en) BENZOXAZINE FOR USE IN THE TREATMENT OF PARKINSON&#39;S DISEASE
MXPA05013239A (en) Amides and method for plant disease control with the same.
DOP2001000252A (en) DERIVED FROM PIRIDINE.
NO951798D0 (en) Therapeutic agents